Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg downgrades Energean to 'hold' as regional risks intensify

(Sharecast News) - Berenberg downgraded Energean on Monday to 'hold' from 'buy' citing uncertainty caused by the increased geopolitical risk and deteriorating security situation in Israel. The company confirmed on 13 June that it had been ordered by the Ministry of Energy and Infrastructure to halt production from its Karish gas field, 90km offshore Israel. The partners of Leviathan, Israel's largest gas field, were also ordered to stop production.

Berenberg said Energean expects regular updates from the Ministry and will update the market in due course, but it is not clear at this stage how long the Karish shut-in is expected to last.

"We have not made any changes to our forecasts at this stage; however, with energy infrastructure appearing to be targeted by both sides in the conflict (the Bazan oil refinery in Haifa has been affected, for example), we believe it is right to take a prudent approach and downgrade Energean to hold," it said.

Berenberg, which kept the price target at 1,000p, pointed out that Energean's Karish gas field accounts for 74% of its 2025 production forecasts, rising to roughly 80% from 2026. It also accounts for around 80% of the bank's total asset NAVs, before any adjustments for net debt.

"We understand the company is exploring its options and believes it would be insulated from any penalties under its gas sale and purchase agreements (GSPAs)," it said.

"However, the if Karish is shut-in for an extended period, this could potentially have a meaningful impact on our production and cash flow forecasts."

At 0940 BST, Energean shares were down 3.4% at 789.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.